|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013018,
umls-concept:C0021756,
umls-concept:C0039198,
umls-concept:C0072980,
umls-concept:C0205217,
umls-concept:C0332281,
umls-concept:C0332307,
umls-concept:C0392756,
umls-concept:C0856825,
umls-concept:C1332714,
umls-concept:C1334114,
umls-concept:C1416467
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-8-26
|
|
pubmed:abstractText |
Previous work has demonstrated that both rapamycin (RAPA) and IL-2 enhance CD4?CD25?Foxp3? regulatory T-cell (Treg) proliferation and function in vitro. We investigated whether the combination of RAPA plus IL-2 could impact acute GVHD induction after bone marrow transplantation (BMT). RAPA plus IL-2 resulted in improved survival and a reduction in acute GVHD lethality associated with an increased expansion of donor type CD4?Foxp3? Tregs and reduced CD4?CD25? conventional T cells (Tcons). RAPA plus IL-2, but not either drug alone, increased both expansion of donor natural Tregs and conversion of induced Tregs from donor CD25? Tcons while IL-2 alone increased conversion of Tregs from CD25? Tcon. RAPA plus IL-2 treatment resulted in less production of IFN-? and TNF, cytokines known to be important in the initiation of acute GVHD. These studies indicate that the pharmacologic stimulation of T cells with IL-2 and the suppression of Tcon proliferation with RAPA result in a selective expansion of functional Tregs and suppression of acute GVHD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
25
|
|
pubmed:volume |
118
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2342-50
|
|
pubmed:meshHeading |
pubmed-meshheading:21734238-Acute Disease,
pubmed-meshheading:21734238-Animals,
pubmed-meshheading:21734238-Bone Marrow Transplantation,
pubmed-meshheading:21734238-Female,
pubmed-meshheading:21734238-Forkhead Transcription Factors,
pubmed-meshheading:21734238-Graft vs Host Disease,
pubmed-meshheading:21734238-Interferon-gamma,
pubmed-meshheading:21734238-Interleukin-2,
pubmed-meshheading:21734238-Interleukin-2 Receptor alpha Subunit,
pubmed-meshheading:21734238-Mice,
pubmed-meshheading:21734238-Mice, Inbred BALB C,
pubmed-meshheading:21734238-Mice, Inbred C57BL,
pubmed-meshheading:21734238-Mice, Transgenic,
pubmed-meshheading:21734238-Sirolimus,
pubmed-meshheading:21734238-T-Lymphocyte Subsets,
pubmed-meshheading:21734238-T-Lymphocytes, Regulatory,
pubmed-meshheading:21734238-Transplantation, Homologous,
pubmed-meshheading:21734238-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea.
|
|
pubmed:publicationType |
Journal Article
|
